Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026)
Bausch Health Companies (BHC) reported Income from Non-Controlling Interests of -$8.0 million for Q1 2026, up 71.43% on a YoY basis from -$4.7 million in Q1 2025, and down 188.89% sequentially from $9.0 million in Q4 2025.
Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 14 years of Income from Non-Controlling Interests data on file, last reported at -$8.0 million in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 71.43% year-over-year to -$8.0 million; the trailing twelve-month figure through Mar 2026 stood at -$17.0 million (up 58.54% YoY), and the FY2025 full-year result was -$37.0 million, down 42.31% from the prior year.
- Income from Non-Controlling Interests fell to -$8.0 million in Q1 2026, from $9.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $9.0 million in Q4 2025 to a low of -$28.0 million in Q1 2025.
- A 5-year average of -$4.8 million and a median of -$5.5 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests surged 200.0% in 2022 and plunged 1200.0% in 2024, its largest moves.
- Tracing BHC's Income from Non-Controlling Interests over 5 years: stood at $4.0 million in 2022, then tumbled by 300.0% to -$8.0 million in 2023, then jumped by 162.5% to $5.0 million in 2024, then soared by 80.0% to $9.0 million in 2025, then tumbled by 188.89% to -$8.0 million in 2026.
- Business Quant data shows BHC's Income from Non-Controlling Interests at -$8.0 million in Q1 2026, $9.0 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Bausch Health Companies | 1.65 Bn | 333.91 Mn | 2.52 Bn | -8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -20.00 Mn |
| Mar 31, 2025 | -28.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | -7.00 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -13.00 Mn |
| Dec 31, 2023 | -8.00 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Dec 31, 2021 | 3.00 Mn |
| Sep 30, 2021 | 3.00 Mn |
| Jun 30, 2021 | 2.00 Mn |
| Mar 31, 2021 | 3.00 Mn |